当地时间1月23日-25日，2025年美国临床肿瘤学会胃肠道肿瘤研讨会（ASCO GI）将在旧金山举行，旨在传递国际消化肿瘤领域的最新研究进展。必博bibo1类创新药安罗替尼、贝莫苏拜单抗和派安普利单抗共有9项研究入选，涉及食管癌、肝细胞癌、胃/胃食管结合部腺癌、结直肠癌领域。

食管癌

ALTER-E005：安罗替尼联合贝莫苏拜单抗术后辅助治疗食管鳞癌的Ⅱ期临床研究

Anlotinib plus benmelstobart as adjuvant therapy in patients with esophageal squamous cell carcinoma: A phase Ⅱ clinical trial (ALTER-E005)

安罗替尼联合派安普利单抗和白蛋白结合型紫杉醇一线治疗晚期食管鳞癌：一项单臂、开放、Ⅱ期临床研究

Anlotinib combined with penpulimab and nab-paclitaxel as first-line treatment for advanced esophageal squamous cell carcinoma (ESCC): A single-arm, open-label phase Ⅱ clinical trial

ALTER-E009初步结果：安罗替尼联合放疗治疗局晚期或晚期食管鳞癌的疗效及安全性，一项多中心、多队列、回顾性临床研究

Preliminary results of the ALTER-E009 study: Efficacy and safety of anlotinib combined with radiotherapy in patients with locally advanced or metastatic esophageal squamous cell carcinoma (ESCC)—A multicenter, multi-cohort retrospective exploratory study

安罗替尼联合卡度尼利单抗新辅助治疗晚期食管鳞癌的单臂、Ⅱ期临床研究

Neoadjuvant cadonilimab plus anlotinib followed by surgery for locally advanced esophageal squamous cell carcinoma: A single arm, phase 2 trial

肝细胞癌

ALTER-H006结果更新：贝莫苏拜单抗联合安罗替尼辅助治疗根治性切除术后伴高复发风险的肝细胞癌的Ⅱ期临床研究

Updated results of ALTER-H006: A phase Ⅱ study of benmelstobart (PD-L1 inhibitor) plus anlotinib as adjuvant therapy in hepatocellular carcinoma (HCC) with high risk of recurrence after radical resection

ALTER-H004研究结果更新：安罗替尼联合TACE术后辅助治疗高复发风险肝细胞癌，一项单臂、多中心、Ⅱ期临床研究

Updated results from ALTER-H004 study: Anlotinib combined with TACE as adjuvant therapy in patients with hepatocellular carcinoma (HCC) at high risk of recurrence after surgery—A single arm, multi-center, phase Ⅱ clinical

胃/胃食管结合部腺癌

贝莫苏拜单抗联合安罗替尼和SOX方案一线治疗PD-L1低表达晚期胃/胃食管结合部腺癌：一项单臂、多中心、Ⅱ期临床研究初步结果

Preliminary results of benmelstobart plus anlotinib combined with SOX in the first-line treatment of advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma with low PD-L1 expression: A single-arm, multicenter phase Ⅱ clinical trial

结直肠癌

安罗替尼联合伊立替康联合或不联合派安普利单抗二线治疗转移性结直肠癌：ZL-IRIAN研究生存结果更新

Updated survival results of ZL-IRIAN: Irinotecan plus anlotinib or in combination with penpulimab as second-line treatment of metastatic colorectal cancer

安罗替尼后线治疗晚期结直肠癌的疗效及安全性

Efficacy and safety of anlotinib as a later-line treatment for advanced colorectal cancer

声明：

1. 本新闻稿旨在促进医药信息的沟通和交流，仅供医疗卫生专业人士参阅，非广告用途。

2. 本公司不对任何药品和/或适应症作推荐。

3. 本新闻稿中涉及的信息仅供参考，不能以任何方式取代专业的医疗指导，也不应被视为诊疗建议。若您想了解具体疾病诊疗信息，请遵从医生或其他医疗卫生专业人士的意见或指导。